Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile
Background: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV). Materials and Methods: A retrospective, consecutive, interventional study was conduct...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=33;epage=36;aulast=Dabir |
| _version_ | 1797245486599503872 |
|---|---|
| author | Supriya Dabir Arthi Mohankumar Manoj G Khatri Mohan Rajan |
| author_facet | Supriya Dabir Arthi Mohankumar Manoj G Khatri Mohan Rajan |
| author_sort | Supriya Dabir |
| collection | DOAJ |
| description | Background: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV). Materials and Methods: A retrospective, consecutive, interventional study was conducted from a tertiary eye hospital, in which treatment-naïve and treatment-switch patients were included. They underwent an intravitreal injection of brolucizumab. The decision to reinject was made based on the presence of fluid on spectral domain optical coherence tomography (SD-OCT) or worsening of vision at follow-up. Outcome measures were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), fluid (subretinal/intraretinal/sub-retinal pigment epithelium fluid) levels, and OCT biomarkers and safety analysis. Results: A total of 59 eyes of 50 patients with a total of 132 intravitreal injections were included. There was a statistically significant improvement (P < 0.05) in BCVA from baseline in logMAR treatment-naïve patients (mean BCVA at baseline 0.6 ± 0.41 and 0.37 ± 0.56). The mean baseline CST of all patients significantly reduced from 582.92 ± 233.11 μm at baseline to 474.06 ± 252.89 μm at the final treatment visit. Thirty-eight percent of patients showed complete resolution of SHRM after a single injection. The interval between each subsequent injection increased from a mean of 67 to 96 days in treatment-switch patients and from 47 to 151 days in treatment-naïve patients. Conclusion: Brolucizumab promises reduced number of injections with longer treatment intervals. |
| first_indexed | 2024-04-24T19:27:40Z |
| format | Article |
| id | doaj.art-7175f54587b14cdea0b036b431519bf7 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-04-24T19:27:40Z |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-7175f54587b14cdea0b036b431519bf72024-03-25T14:38:33ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892024-01-017213333610.4103/IJO.IJO_927_23Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profileSupriya DabirArthi MohankumarManoj G KhatriMohan RajanBackground: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV). Materials and Methods: A retrospective, consecutive, interventional study was conducted from a tertiary eye hospital, in which treatment-naïve and treatment-switch patients were included. They underwent an intravitreal injection of brolucizumab. The decision to reinject was made based on the presence of fluid on spectral domain optical coherence tomography (SD-OCT) or worsening of vision at follow-up. Outcome measures were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), fluid (subretinal/intraretinal/sub-retinal pigment epithelium fluid) levels, and OCT biomarkers and safety analysis. Results: A total of 59 eyes of 50 patients with a total of 132 intravitreal injections were included. There was a statistically significant improvement (P < 0.05) in BCVA from baseline in logMAR treatment-naïve patients (mean BCVA at baseline 0.6 ± 0.41 and 0.37 ± 0.56). The mean baseline CST of all patients significantly reduced from 582.92 ± 233.11 μm at baseline to 474.06 ± 252.89 μm at the final treatment visit. Thirty-eight percent of patients showed complete resolution of SHRM after a single injection. The interval between each subsequent injection increased from a mean of 67 to 96 days in treatment-switch patients and from 47 to 151 days in treatment-naïve patients. Conclusion: Brolucizumab promises reduced number of injections with longer treatment intervals.http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=33;epage=36;aulast=Dabirage-related macular degenerationanti-vascular endothelial growth factorbrolucizumabchoroidal neovascular membraneidiopathic polypoidal choroidal vasculopathyintraretinal fluidpigment epithelial detachmentsubretinal fluidsubretinal hyperreflective membrane |
| spellingShingle | Supriya Dabir Arthi Mohankumar Manoj G Khatri Mohan Rajan Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile Indian Journal of Ophthalmology age-related macular degeneration anti-vascular endothelial growth factor brolucizumab choroidal neovascular membrane idiopathic polypoidal choroidal vasculopathy intraretinal fluid pigment epithelial detachment subretinal fluid subretinal hyperreflective membrane |
| title | Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile |
| title_full | Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile |
| title_fullStr | Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile |
| title_full_unstemmed | Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile |
| title_short | Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile |
| title_sort | brolucizumab in age related macular neovascularization brain study efficacy optical coherence tomography biomarkers and safety profile |
| topic | age-related macular degeneration anti-vascular endothelial growth factor brolucizumab choroidal neovascular membrane idiopathic polypoidal choroidal vasculopathy intraretinal fluid pigment epithelial detachment subretinal fluid subretinal hyperreflective membrane |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=33;epage=36;aulast=Dabir |
| work_keys_str_mv | AT supriyadabir brolucizumabinagerelatedmacularneovascularizationbrainstudyefficacyopticalcoherencetomographybiomarkersandsafetyprofile AT arthimohankumar brolucizumabinagerelatedmacularneovascularizationbrainstudyefficacyopticalcoherencetomographybiomarkersandsafetyprofile AT manojgkhatri brolucizumabinagerelatedmacularneovascularizationbrainstudyefficacyopticalcoherencetomographybiomarkersandsafetyprofile AT mohanrajan brolucizumabinagerelatedmacularneovascularizationbrainstudyefficacyopticalcoherencetomographybiomarkersandsafetyprofile |